Joe Biden’s recent diagnosis of "aggressive" prostate cancer has sparked concerns about how far the disease has advanced. The former president’s prostate cancer has been characterized by a Gleason ...
Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...
Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...
A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer. Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type ...
Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...
Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic ...
InvestorsHub on MSN
Pfizer’s TALZENNA combination shows progress against prostate cancer
Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Let me introduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results